Because FDG PET imaging is clinically useful for the evaluation of a number of diseases, especially cancer but also AD, FDG PET is readily available at many research centers and now also in academic medical (clinical) centers, and it has been explored in conjunction with either peripheral or central insulin challenges as a proxy measure of BIR. The gene discussed is INS; the disease is cancer.